Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-08-25
1999-11-16
Huff, Sheela
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, A61K 3800
Patent
active
059858320
ABSTRACT:
It has been found that two proteins produced by human osteoclasts inhibit osteoclast formation in bone marrow cultures and inhibit bone resorption in a fetal long bone assay. One of the proteins is identical to an Ly6 gene family protein and homologous to the Sca2 antigen, Ly6A. The second, OIP-2, is a novel protein not previously identified. The discovery of the osteoclast inhibition property of the OIP proteins suggests the therapeutic potential for patients with disordered osteoclast activity in such conditions as osteoporosis.
REFERENCES:
Akatsu et al., "Preparation and characterization of a mouse osteoclast-like multinucleated cell population," J. Bone Miner. Res. 7(11):1297-1306, 1992.
Abdulkarim et al., "Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae," J. Bone Miner. Res. 6(1):3-8, 1991.
Alcantara et al., "Transcriptional regulation of the tartrate-resistant acid phosphatase (TRAP) gene by iron," Biochem. J., 298:421-425, 1994.
Bartkiewicz et al., "Characterization of the osteoclast vacuolar H.sup.+ -ATPase B-subunit," Gene 160:157-164, 1995.
Blake et al., "Ly-6 in kidney is widely expressed on Tubular epithelium and vascular endothelium and is up-regulated by interferon gamma," J. Am. Soc. Nephrol., 4:(5):1140-1150), 1993.
Boyce et al., "Targeting simian virus 40 T antigen to the osteoclast in transgenic mice causes osteoclast tumors and transformation and apoptosis of osteoclasts," Endo., 136(12):5751-5759, 1995.
Brakenhoff et al., "The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion," J. Cell. Biol., 129:1677-1689, 1995.
Brandi et al., "Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms," Proc. Natl. Acad. Sci. USA, 92:2954-2958, 1995.
Chenu et al., "Prostaglandin E.sub.2 inhibits formation of osteoclastlike cells in long-term human marrow cultures but is not a mediator of the inhibitory effects of transforming growth factor .beta.," J. Bone Miner. Res., 5(7):677-681, 1990.
Chenu et al., "Transforming growth factor .beta. inhibits formation of osteoclast-like cells in long-term human marrow cultures," Proc. Natl. Acad. Sci. USA 85:5683-5687, 1988.
Classon et al., "Mouse stem cell antigen Sca-2 is a member of the Ly-6 family of cell surface proteins," Proc. Natl. Acad. Sci. USA, 91:5296-5300, 1994.
Coleman et al., "Osteoclast inhibition for the treatment of bone metastases," Cancer Treatment Reviews, 19:79-103, 1993.
Davies et al., "The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor," J. Cell Biol., 109:1817-1826, 1989.
De La Mata et al., Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo, J. Clin. Invest., 95:2846-2852, 1995.
Devlin, et al., "Interleukin-6: A potential mediator of the massive osteolysis in patients with Gorham-Stout disease," J. Clin. Endo. and Metabolism, 81(5):1893-1897, 1996.
Devlin et al., "Annexin II increases osteoclast (OCL) formation by stimulating the proliferation of osteoclast precursors in human marrow cultures," J. Bone Miner. Res., 10:S323, (Suppl. 1), ISSN 0884-0431, Abstract No. M283, 1995.
Fisher et al., "Inhibition of osteoclastic bone resorption in vivo by echistatin, an `Arginyl-Glycly-Asparty` (RGD)-containing protein," Endo., 132(3):1411-1413, 1993.
Fleming et al., "Multiple glycosylphosphatidylinositol-Anchored Ly-6 molecules and transmembrane Ly-6E mediate inhibition of IL-2 production," J. Immunol, 153:1955-1962, 1994.
Gallwitz et al., "5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices," J. Biol. Chem., 268(14):10087-10094, 1993.
Jilka et al., "Increased osteoclast development after estrogen loss: Mediation by Interleukin-6," Science, 257:88-91, 1992.
Kurihara, et al., "IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release," J. Immunol., 144(11):4226-4230, 1990.
Kurihara et al., "Identification of committed mononuclear precursors for osteoclast-like cells formed in long term human marrow cultures," Endo., 126(5):2733-2741, 1990.
Horowitz et al., "Expression and regulation of Ly-6 differentiation antigens by murine osteoblasts," Endo., 135(3):1032-1043, 1994.
MacDonald et al., "Formation of multinucleated cells that respond to osteotropic hormones in long term human bone marrow cultures," Endo., 120(6):2326-2333, 1987.
Oursler, Merry Jo, "Osteoclast synthesis and secretion and activation of latent transforming growth factor .beta.," J. Bone Miner. Res., 9(4):443-452, 1994.
Reddy et al., "Cloning and characterization of a novel autocrine osteoclast (OCL) stimulating factor (OSF)," J. Bone Miner. Res., 10:S325, (Suppl. 1), ISSN 0884-0431, Abstract No. M292, 1995.
Reddy et al., "Inhibition of tartrate-resistant acid phosphatase gene expression by hemin and protoporphyrin IX. Identification of a hemin-responsive inhibitor of transcription," Blood, 88(6):2288-2297, 1996.
Reddy et al., "Characterization of the mouse tartrate-resistant acid phosphatase (TRAP) gene promoter," J. Bone Miner. Res., 10(4):601-606, 1995.
Reddy et al., "Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone," J. Bone Miner. Res., 9(5):753-757, 1994.
Reddy et al., Tartrate-Resistant acid phosphatase gene expression as a facile reporter gene for screening transfection efficiency in mammalian cell cultures, Bio Techniques 15(3):444-447, 1993.
Roodman, G.D., "Application of bone marrow cultures to the study of osteoclast formation and osteoclast precursors in man," Calcif Tissue Int., 56(Suppl. 1):S22-S23, 1995.
Simonet et al., "Osteoprotegerin: A novel secreted protein involved in the regulation of bond density," Cell, 89:309-319, 1997.
Takahashi et al., "Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures." Endo., 122(4):1373-1382, 1988.
Takahashi et al., "Cloning and identification of annexin II as an autocrine/paracrine factor that increases formation and bond resorption," J. Biol. Chem., 269(46):28696-28701, 1994.
Takahashi et al., "Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation," J. Clin. Invest., 95:167-171, 1995.
Takahashi et al., "Development and characterization of a human marrow stromal cell line that enhances osteoclast-like cell formation," Endo., 136(4):1441-1449, 1995.
Toshiyuki et al., "Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer," Cancer Research, 55:1989-1993, 1995.
Uy et al., "Use of an in vivo model to determine the effects of interleukin-1 on cells at different stages in the osteoclast lineage," J. Bone Miner. Res., 10(2):295-301, 1995.
Uy et al., "Effects of parathyroid hormone (PTH)-related protein and PTH on osteoclasts and osteoclast precursors in vivo," Endo., 136(8):3207-3212, 1995.
Choi Sun-Jin
Reddy Sakamuri V.
Roodman G. David
Board of Regents , The University of Texas System
Huff Sheela
LandOfFree
Compositions and methods of use for osteoclast inhibitor factors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods of use for osteoclast inhibitor factors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods of use for osteoclast inhibitor factors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1324764